TY - JOUR
T1 - Extended Endocrine Therapy for Early-Stage Breast Cancer
T2 - How Do We Decide?
AU - Walsh, Elaine M.
AU - Nunes, Raquel
AU - Wilkinson, Mary J.
AU - Santa-Maria, Cesar A.
N1 - Funding Information:
Elaine M. Walsh, Raquel Nunes, and Mary J. Wilkinson declare no conflict of interest. Cesar A. Santa-Maria has received research funding from Pfizer, AstraZeneca, Tesaro, and Genentech and has participated on advisory boards for Genomic Health, Polyphor, Bristol-Myers Squibb, Halozyme Therapeutics, and Athenex.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Purpose of Review: While the majority of hormone receptor–positive breast cancers are diagnosed at an early stage, a significant proportion of patients will develop disease recurrence, especially late disease recurrence, despite current therapeutic approaches. In this review, we examine the data pertaining to the choice of endocrine and extended endocrine therapy, outline how to identify patients that may benefit from extended therapy, and discuss prognostic tools to assist with patient selection. Recent Findings: The risk of breast cancer recurrence persists after 5 years, is cumulative, and is indefinite. In attempts to mitigate these risks, studies have evaluated the use of extended endocrine therapy. Overall survival benefit has been demonstrated with extended tamoxifen, whereas extended aromatase inhibitors have shown modest disease-free survival benefit. Summary: Therapeutic approaches for individual patients will depend on the perceived risk of recurrence, likely benefit of extended therapy, tolerability of current endocrine therapy, and patient preference.
AB - Purpose of Review: While the majority of hormone receptor–positive breast cancers are diagnosed at an early stage, a significant proportion of patients will develop disease recurrence, especially late disease recurrence, despite current therapeutic approaches. In this review, we examine the data pertaining to the choice of endocrine and extended endocrine therapy, outline how to identify patients that may benefit from extended therapy, and discuss prognostic tools to assist with patient selection. Recent Findings: The risk of breast cancer recurrence persists after 5 years, is cumulative, and is indefinite. In attempts to mitigate these risks, studies have evaluated the use of extended endocrine therapy. Overall survival benefit has been demonstrated with extended tamoxifen, whereas extended aromatase inhibitors have shown modest disease-free survival benefit. Summary: Therapeutic approaches for individual patients will depend on the perceived risk of recurrence, likely benefit of extended therapy, tolerability of current endocrine therapy, and patient preference.
KW - Breast cancer
KW - Endocrine therapy
KW - Extended endocrine therapy
KW - Hormone receptor
UR - http://www.scopus.com/inward/record.url?scp=85091987766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091987766&partnerID=8YFLogxK
U2 - 10.1007/s11912-020-00988-7
DO - 10.1007/s11912-020-00988-7
M3 - Review article
C2 - 33015752
AN - SCOPUS:85091987766
VL - 22
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 12
M1 - 123
ER -